Trial Profile
A phase I randomized, placebo-controlled, alternating-panel, single-rising IV dose study of SCY-078 in healthy subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2016
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary) ; Ibrexafungerp (Primary)
- Indications Mycoses
- Focus Adverse reactions
- 08 Aug 2016 Results from this trial are expected in November 2016, according to a SCYNEXIS media release.
- 20 Jun 2016 Interim sub-analysis (n=14) from this trial were presented at ASM Microbe 2016, according to a Scynexis media release.
- 20 Jun 2016 Results (n=14) published in a Scynexis media release.